ArticleFrontiers in oncology2026
A study on the effect of remimazolam on cellular immune function during the perioperative period in older adults who are having laparoscopic surgery for colorectal cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the effect of remimazolam on perioperative cellular immune function in elderly patients undergoing laparoscopic colorectal cancer surgery. Methods: Sixty elderly patients were randomly assigned to receive either propofol (Group P, n=30) or remimazolam (Group R, n=30) for anesthesia induction and maintenance. Hemodynamic parameters, Bispectral Index (BIS), emergence time, vasopressor requirement, and adverse reactions were recorded. T lymphocyte subsets (CD3 Results: Mean arterial pressure (MAP) at T5 was significantly higher in Group R compared to Group P (P<0.05). Group R had a significantly lower intraoperative vasopressor usage rate (P<0.05) but a longer emergence time (P<0.05). CD4 Conclusion: No statistically significant difference was detected between remimazolam and propofol in the primary endpoint (NK cell percentage at 24 hours postoperatively); however, this superiority-designed study was not powered to demonstrate equivalence. Remimazolam reduced intraoperative vasopressor requirement but may prolong emergence time, with a temporary decrease in CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.